Compugen Ltd
NASDAQ:CGEN
ROE
Return on Equity
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
ROE Across Competitors
| Country | Company | Market Cap | ROE | ||
|---|---|---|---|---|---|
| IL |
|
Compugen Ltd
NASDAQ:CGEN
|
127.1m USD |
-24%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
4%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
150.9B USD |
14%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
134.5B USD |
7%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
12%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.1B CHF |
7%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.2B USD |
21%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
181.3B CNY |
20%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
24B USD |
22%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
23.3B USD |
-499%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19B EUR |
5%
|
Compugen Ltd
Glance View
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
See Also
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
Based on Compugen Ltd's most recent financial statements, the company has ROE of -23.6%.
You don't have any saved screeners yet